IRulya Therapeutics Inc. posted its Corporate Presentation, dated October 2026
On EDGAR, not explained yet
IRulya Therapeutics
IRLA
Listing: 2 notices since Mar 2026, 1 open (newest Sep 4)
- 8-K item 3.01, Sep 4, 2026 Listing compliance deadline: Feb 27, 2027, Stockholders' equity (Nasdaq 5450(b)(1)(A))
- 8-K item 3.01, Mar 20, 2026 rule and cure date not stated in the filing
Dilution Known so far: no new shares beyond today's 1.0M · shelf room about $21.3M · not yet read: warrants, converts, options, ATM; 86.7K registered for resale, likely already outstanding, not counted. Every source
Net loss $75.5M, diluted EPS −$12.31 in the quarter ended Jun 30, 2026, from a 10-Q filed .
Next: earnings expected ~Nov 12; 10-Q expected ~Nov 12 (deadline Nov 16)
- Cash and short-term investments$116MCash and short-term investments up $81.3M vs the Jun 2025 quarter
- Operating burn, last quarter$18.9MBurn up $7.5M vs the Jun 2025 quarter
- Shares outstanding1.0M+279% from 269K on Aug 5, 2025, adjusted for two reverse splits, 1-for-10 by May 4, 2026 and 1-for-20 by Aug 7, 2026
From the 10-Q 0001193125-26-352201 on EDGAR
IRulya Therapeutics says Dirk Thye resigned as Chief Executive Officer
Departure; charter or bylaw change; Reg FD disclosure; other event Items 5.02, 5.03, 7.01 and 8.01 on EDGAR
On EDGAR, not explained yet.
Cash runway and key numbers
About 8.7 quarters of cash at the average operating burn of the last 2 quarters, which would last to about Sep 2028.
- Cash and short-term investments
- $116M
- Operating burn a quarter, average of the last 2 quarters
- $13.3M
Operating burn by quarter: $7.6M in the Mar 2026 quarter, $18.9M in the Jun 2026 quarter; the runway uses their average, $13.3M.
From the 10-Q 0001193125-26-352201 for the period ended Jun 30, 2026, as tagged in its XBRL. An estimate from reported figures, not a forecast or advice.
Last quarter’s operating cash flow is the 6-month total in 0001193125-26-352201 less the 3-month total in 0001193125-26-217098.
Every quarter as a table
| Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | — | $40.8M | $31.6M | $34.7M | $26.3M | $17.8M | $18.2M | $116M |
| Quarterly burn | $7.3M | $7.6M | $9.6M | $11.4M | $9.9M | $10.5M | $7.6M | $18.9M |
| Shares outstanding | 44.0Mas of Nov 5 | 44.0Mas of Mar 13 | 45.5Mas of May 6 | 53.7Mas of Aug 5 | 55.7Mas of Nov 6 | 163Mas of Apr 9 | 16.3Mas of May 4 | 1.0Mas of Aug 7 |
| R&D | $4.9M | $5.8M | $8.1M | $6.6M | $8.1M | $12.6M | $6.8M | $5.5M |
What IRulya Therapeutics does
Products
eDSP In development
eDSP is a drug candidate that uses AIDE technology to encapsulate DSP into a patient's own red blood cells for the treatment of rare diseases. Source
Key ingredient: DSP
AIDE technology platform Platform
AIDE technology is a drug/device combination that uses an automated process to encapsulate a drug into a patient's own red blood cells for improved drug delivery. Source
Key ingredient: autologous red blood cells
RCL Device
RCL is a non-invasive automated device used in the AIDE technology platform to encapsulate a drug into a patient's own red blood cells. Source
Key ingredient: non-invasive automated device
- Employees
- 38 Source
From the 10-K filed Apr 10, 2026, Item 1, Business. Open the filing. Each line links to the passage it restates. The company's own description, summarized; not investment advice.
All filings
Results, 8-Ks and Major or Notable filings come first, then registrations and share actions, then everything else, newest first. Routine filings are kept here unmarked; insider filings are summed up in one line.
Results, 8-Ks and key filings
8-KIRulya TherapeuticsIRLALIVEEDGAR 8-KIRulya TherapeuticsIRLALIVEEDGAR IRulya Therapeutics says Dirk Thye resigned as Chief Executive Officer
Departure; charter or bylaw change; Reg FD disclosure; other event
On EDGAR, not explained yet
8-KIRulya TherapeuticsIRLALIVEEDGAR Quince Therapeutics, Inc., held a special meeting of stockholders.
Leadership change; charter or bylaw change; shareholder vote
On EDGAR, not explained yet
8-KIRulya TherapeuticsIRLALIVEEDGAR IRulya Therapeutics reports an executive or board change
On EDGAR, not explained yet
8-KIRulya TherapeuticsIRLALIVEEDGAR Acquisition or sale; leadership change
On EDGAR, not explained yet
8-KIRulya TherapeuticsIRLALIVEEDGAR IRulya Therapeutics reports an exchange listing deficiency notice
On EDGAR, not explained yet
8-KIRulya TherapeuticsIRLALIVEEDGAR IRulya Therapeutics reports an executive or board change
On EDGAR, not explained yet
8-KIRulya TherapeuticsIRLALIVEEDGAR IRulya Therapeutics discloses other events
On EDGAR, not explained yet
13 older filings, Aug 14 to Dec 16, 2022
10-QIRulya TherapeuticsIRLALIVEEDGAR Quarter ended Jun 30, 2026: net loss $75.5M, diluted EPS −$12.31
On EDGAR, not explained yet
8-KIRulya TherapeuticsIRLALIVEEDGAR Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
On EDGAR, not explained yet
8-KIRulya TherapeuticsIRLALIVEEDGAR IRulya Therapeutics reports an executive or board change
On EDGAR, not explained yet
8-K/AIRulya TherapeuticsIRLALIVEEDGAR IRulya Therapeutics discloses other events (amended)
On EDGAR, not explained yet
8-K/AIRulya TherapeuticsIRLALIVEEDGAR IRulya Therapeutics changes shareholder rights (amended)
On EDGAR, not explained yet
8-KIRulya TherapeuticsIRLALIVEEDGAR IRulya Therapeutics changes shareholder rights and amends its charter or bylaws
Shareholder rights change; charter or bylaw change
On EDGAR, not explained yet
8-KIRulya TherapeuticsIRLALIVEEDGAR IRulya Therapeutics reports shareholder vote results
On EDGAR, not explained yet
8-KIRulya TherapeuticsIRLALIVEEDGAR NOTABLE10-QIRulya TherapeuticsIRLALIVEEDGAR Quarter ended Jun 30, 2025: net loss $16.0M, diluted EPS −$0.34
8-KIRulya TherapeuticsIRLALIVEEDGAR IRulya Therapeutics makes a Regulation FD disclosure and discloses other events
3 more 8-K filings, Apr 5, 2023 to Dec 16, 2022
8-KIRulya TherapeuticsIRLALIVEEDGAR IRulya Therapeutics signs a material agreement, changes shareholder rights and 2 other items
Material agreement; shareholder rights change; charter or bylaw change; other event
8-KIRulya TherapeuticsIRLALIVEEDGAR 8-KIRulya TherapeuticsIRLALIVEEDGAR IRulya Therapeutics reports an exchange listing deficiency notice
11 insider filings (Forms 3, 4, 5 and 144) in this list. Every IRLA insider trade
Financing and share filings
EFFECTIRulya TherapeuticsIRLALIVEEDGAR Registration declared effective Aug 24
On EDGAR, not explained yet
S-3/AIRulya TherapeuticsIRLALIVEEDGAR Amended shelf registration; new shares or resale not read yet
On EDGAR, not explained yet
S-3IRulya TherapeuticsIRLALIVEEDGAR Shelf registration; new shares or resale not read yet
On EDGAR, not explained yet
424B5IRulya TherapeuticsIRLALIVEEDGAR S-3IRulya TherapeuticsIRLALIVEEDGAR 424B5IRulya TherapeuticsIRLALIVEEDGAR EFFECTIRulya TherapeuticsIRLALIVEEDGAR S-3IRulya TherapeuticsIRLALIVEEDGAR 1 older filing, May 19, 2022
Other filings
Schedule 13GIRulya TherapeuticsIRLALIVEEDGAR 2 13G filings
Show all 2
- SCHEDULE 13GOwnership stake disclosure
- SCHEDULE 13GOwnership stake disclosure
S-8IRulya TherapeuticsIRLALIVEEDGAR Employee stock plan registration
On EDGAR, not explained yet
DEFA14AIRulya TherapeuticsIRLALIVEEDGAR On EDGAR, not explained yet
DEF 14AIRulya TherapeuticsIRLALIVEEDGAR On EDGAR, not explained yet
Schedule 13GIRulya TherapeuticsIRLALIVEEDGAR 4 13G filings
Show all 4
- SCHEDULE 13GOwnership stake disclosure
- SCHEDULE 13GOwnership stake disclosure
- SCHEDULE 13G/AOwnership stake disclosure (amended)
- SCHEDULE 13GOwnership stake disclosure
Schedule 13GIRulya TherapeuticsIRLALIVEEDGAR Squadron Master Fund reports a 5.6% stake in Quince Therapeutics
On EDGAR, not explained yet
PRE 14AIRulya TherapeuticsIRLALIVEEDGAR On EDGAR, not explained yet
Schedule 13G/AIRulya TherapeuticsIRLALIVEEDGAR S.p.A. Genextra updates a passive stake in IRulya Therapeutics
- 0 shares owned
- 0% of class
- S.p.A. Genextra, Francesco Micheli, and Matteo Bruno Renzulli filed jointly
Filed by S.p.A. Genextra
4 older filings, Apr 23, 2025 to May 20, 2022
Shares registered for resale
Known so far: no new shares beyond today's 1.0M · shelf room about $21.3M · not yet read: warrants, converts, options, ATM.
86.7K registered for resale, already counted in today's shares where issued; all likely already outstanding.
- 17.3M shares registered for resale (86.7K after two reverse splits, 1-for-10 by May 4, 2026 and 1-for-20 by Aug 7, 2026; 8.5% of today's 1.0M) under the S-3 of Jul 25, 2025, newest prospectus the 424B5 of Aug 5, 2025; likely already outstanding
Not read yet: warrants, convertible notes, options and RSUs and an ATM program.
Listing compliance
1 open of 2 listing notices from 8-K item 3.01.
- Sep 4, 2026 Stockholders' equity (Nasdaq 5450(b)(1)(A)), cure by Feb 27, 2027
- Mar 20, 2026 8-K item 3.01 notice; rule and cure date not stated, see the filing
Dates and rules are as stated in each 8-K item 3.01 filing; a blank means the filing did not state one. Read the filing for the full terms. All open notices
Trading halts
No trading halts for IRLA since Feb 22, 2019, when SEC Tracker began reading the Nasdaq Trader feed.
Halt times and codes from the Nasdaq Trader trade halts feed, which lists Nasdaq and other exchange halts. Filings matched by SEC Tracker from EDGAR by company and time. Not investment advice. All recent halts
Coming up
- Earnings, expected
- 10-Q, expected (deadline Nov 16)
Stated dates are as each filing on EDGAR gives them; an expected date is estimated from the company's past filing dates, the same estimate as the top of the page. Not investment advice.
IRulya Therapeutics shares and listing
From the company's own filings; each row names its source. Not investment advice.
- Shares outstandingas of Aug 7, 2026 (10-Q filed Aug 14)1Mwarrants, notes and options not read yet, so fully diluted is not known
- Listing compliance8-K item 3.012 notices since Mar 2026, 1 opencure by Feb 27, 2027